Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 19/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13733200 | 0.85 | GPR119 (0.44) | GPR119CYP2C9 | |
| SCHEMBL288499 | 0.85 | GPR119 (0.41) | GPR119CYP2C9PIK3CD | |
| SCHEMBL288948 | 0.84 | GPR119 (0.65) | GPR119CYP2C9 | |
| SCHEMBL1065920 | 0.84 | GPR119 (0.55) | GPR119PIK3CD | |
| SCHEMBL13272803 | 0.83 | GPR119 (0.48) | GPR119CYP2C9PIK3CD | |
| SCHEMBL288648 | 0.81 | PIK3CD (0.39) | GPR119CYP2C9PIK3CD | |
| SCHEMBL298803 | 0.81 | PIK3CD (0.39) | GPR119CYP2C9PIK3CD | |
| SCHEMBL1768128 | 0.81 | PIK3CD (0.39) | GPR119CYP2C9PIK3CD | |
| SCHEMBL12266042 | 0.81 | GPR119 (0.38) | GPR119 | |
| SCHEMBL3806633 | 0.81 | GPR119 (0.54) | GPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2625177-B1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2015-07-29 | — | — | EP | disclosed |
| US-8785463-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-22 | — | — | US | disclosed |
| US-20130252980-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2013-09-26 | — | — | US | disclosed |
| US-20130072427-A1 | GPR 119 MODULATORS | PFIZER INC. | 2013-03-21 | — | — | US | disclosed |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC | 2012-11-22 | — | — | US | disclosed |
| EP-2504342-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | Pfizer Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2480551-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2011061679-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | PFIZER INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011036576-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| WO-2010075269-A1 | PYRIMIDINE DERIVATIVES AS GPCR MODTTLATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES | SCHERING CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | GPR119 1/4885CYP2C9 722/4885PIK3CD 2858/4885 |
| US-20130072427-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CYP2C9 1406/4885PIK3CD 2502/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | GPR119 1/4885CYP2C9 1406/4885PIK3CD 2502/4885 |
| US-20130252980-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR27, GPR4 | GPR119 1/4885CYP2C9 828/4885PIK3CD 2231/4885 |
| US-20120295845-A1 | IMIDAZO-PYRAZOLES AS GPR119 INHIBITORS | GPR3, GPR119, GPR84 | GPR119 2/4885CYP2C9 1481/4885PIK3CD 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.